Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Ocugen, Inc.NASDAQ: OCGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $590K fell 35.1% year over year, behind the -23.3% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +70.7% a year.
Context
- Depreciation & amortization amounted to 54.1% of revenue in FY2025, up 5.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -23.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.39M USD
- Year-over-year change
- +21.4%
- 4-year CAGR
- +79.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.39M | +21.4% |
| FY2024 | 2024-12-31 | 1.97M | +179.5% |
| FY2023 | 2023-12-31 | 704K | +46.7% |
| FY2022 | 2022-12-31 | 480K | +109.6% |
| FY2021 | 2021-12-31 | 229K | — |
Depreciation & Amortization vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 depreciation & amortization of $2.07M is the 3rd largest of the 10 companies compared; the peer median is $723K.
- Its year-over-year change of -23.3% is the 6th highest of 10, against a peer median of -12.7%.
- Depreciation & amortization amounts to 46.4% of revenue for OCGN, versus a peer median of 4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $3.22M | +1.1% | -1.1% | — | |
| LTM Mar 2026 | $2.07M | -23.3% | +70.7% | 46.4% | |
| LTM Mar 2026 | $1.84M | -31.3% | -31.1% | 2.3% | |
| LTM Mar 2026 | $1.33M | -12.7% | -16.8% | — | |
| LTM Mar 2026 | $1.32M | -227.7% | +0.4% | 13.4% | |
| LTM Mar 2026 | $723K | +20.9% | -1.3% | 4.9% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
| LTM Mar 2026 | $468K | -128.3% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding OCGN) | $723K | -12.7% | -1.2% | 4.9% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.